Abstract
Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
| Original language | English |
|---|---|
| Pages (from-to) | 1164-1168 |
| Number of pages | 5 |
| Journal | Clinical and Vaccine Immunology |
| Volume | 21 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1 Jan 2014 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Clinical Biochemistry
- Microbiology (medical)
Cite this
Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United Kingdom. / Ramasamy, Maheshi N.; Clutterbuck, Elizabeth A.; Haworth, Kathryn; Bowman, Jaclyn; Omar, Omar; Thompson, Amber J.; Blanchard-Rohner, Geraldine; Yu, Ly Mee; Snape, Matthew D.; Pollard, Andrew J.
In: Clinical and Vaccine Immunology, Vol. 21, No. 8, 01.01.2014, p. 1164-1168.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United Kingdom
AU - Ramasamy, Maheshi N.
AU - Clutterbuck, Elizabeth A.
AU - Haworth, Kathryn
AU - Bowman, Jaclyn
AU - Omar, Omar
AU - Thompson, Amber J.
AU - Blanchard-Rohner, Geraldine
AU - Yu, Ly Mee
AU - Snape, Matthew D.
AU - Pollard, Andrew J.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
AB - Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
UR - http://www.scopus.com/inward/record.url?scp=84906658385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906658385&partnerID=8YFLogxK
U2 - 10.1128/CVI.00099-14
DO - 10.1128/CVI.00099-14
M3 - Article
VL - 21
SP - 1164
EP - 1168
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
SN - 1556-6811
IS - 8
ER -